Chaft, Jamie E.
Rimner, Andreas
Weder, Walter
Azzoli, Christopher G.
Kris, Mark G.
Cascone, Tina
Article History
Accepted: 10 March 2021
First Online: 28 April 2021
Competing interests
: J.E.C. reports consulting fees from AstraZeneca, Bristol–Myers Squibb, Flame Biosciences, Genentech, Merck, and Novartis and clinical research funding to Memorial Sloan Kettering Cancer Center from AstraZeneca, Bristol–Myers Squibb, Genentech and Merck. A.R. reports grants from Boehringer Ingelheim, Pfizer, and Varian Medical Systems, grants and personal fees from AstraZeneca and Merck, personal fees from Cybrexa, More Health and Research to Practice, and non-financial support from Philips–Elekta, outside the submitted work. W.W. reports advisory board and speaker fees from AstraZeneca as well as teaching grant and speaker fees from Covidien–Medtronic. M.G.K. reports personal fees from AstraZeneca, Daiichi–Sankyo, Pfizer and Regeneron from outside the submitted work and honoraria for participation in educational programmes from AstraZeneca, AXIS, Carvive Systems, Creative Educational Concepts, i3 Health, Intellisphere, OncLive, Paradigm Medical Communications, Peerview, Physicians Education Resources, Prime Oncology, Research to Practice and WebMD. Funds for travel and lodging as well as food and beverage have been provided by AstraZeneca, Genentech, Pfizer and Regeneron. M.G.K. is an employee of Memorial Sloan Kettering. Memorial Sloan Kettering has received research funding from Genentech Roche, the Lung Cancer Research Foundation, the US National Cancer Institute and PUMA Biotechnology for research conducted by M.G.K. Memorial Sloan Kettering has licensed testing for EGFR T790M to MolecularMD. T.C. reports consulting fees from Bristol–Myers Squibb and MedImmune–AstraZeneca, advisory role fees from Bristol–Myers Squibb and EMD Serono, and clinical research funding to MD Anderson Cancer Center from Boehringer Ingelheim, Bristol–Myers Squibb, EMD Serono, and MedImmune–AstraZeneca. C.G.A. declares no competing interests.